Premium
P2‐020: Serum Granulocyte Colony Stimulating Factor and Alzheimer's Disease
Author(s) -
Barber Robert,
O'Bryant Sid,
Reisch Joan,
Doody Rachelle,
Fairchild Thomas,
Adams Perrie,
Royall Donald,
DiazArrastia Ramon
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.910
Subject(s) - medicine , dementia , disease , alzheimer's disease , granulocyte colony stimulating factor , oncology , neurotrophic factors , clinical dementia rating , chemotherapy , receptor
BACKGROUNDGranulocyte colony-stimulating factor (G-CSF) promotes the survival and function of neutrophils. G-CSF is also a neurotrophic factor, increasing neuroplasticity and suppressing apoptosis.METHODSWe analyzed G-CSF levels in 197 patients with probable Alzheimer's disease (AD) and 203 cognitively normal controls (NCs) from a longitudinal study by the Texas Alzheimer's Research and Care Consortium (TARCC). Data were analyzed by regression with adjustment for age, education, gender and APOE4 status.RESULTSSerum G-CSF was significantly lower in AD patients than in NCs (β = -0.073; p = 0.008). However, among AD patients, higher serum G-CSF was significantly associated with increased disease severity, as indicated by lower Mini-Mental State Examination scores (β = -0.178; p = 0.014) and higher scores on the global Clinical Dementia Rating (CDR) scale (β = 0.170; p = 0.018) and CDR Sum of Boxes (β = 0.157; p = 0.035).CONCLUSIONSG-CSF appears to have a complex relationship with AD pathogenesis and may reflect different pathophysiologic processes at different illness stages.